Evolving Medicine Enhancing Lives

Combining innovative formulations with proprietary medical device technology to reduce suffering caused by pain, addiction and mental health conditions.


Safe solutions to pain management have been elusive.

 Each year up to 160,000 Americans may become addicted to opioids as a result of standard pain management (Pino & Covington, 2019) with a substantial number of these patients dying as a result of their dependence.


 The U.S. is facing an opioid crisis.

Nearly 841,000 people have died since 1999 from a drug overdose with over 70% of these  overdose deaths in 2019 involving an opioid. During COVID-19 we have seen a continued rise in addiction rates, highlighting the urgent need for alternate safe and effective options.  The gap for pain management continues to be effective, non-opioid therapies that patients can take in the clinic and at home.

Bexson Biomedical is meeting this challenge.

We are developing new subcutaneous formulations and a proprietary controlled delivery system to address multiple large-market indications in need of new treatments.

Our lead formulation repurposes ketamine for controlled, low-dose subcutaneous delivery, offering a meaningful alternative to opioid-centered pain management to millions of people suffering from pain and mental health conditions.

Pairing Modular Formulation and Delivery Technology

Our efforts to repurpose ketamine for pain management have resulted in two modular technology platforms

Formulation Platform:

Modular formulation technology for optimizing subcutaneous drug formulations.

Drug Delivery Platform:

A dynamic programmable drug delivery platform that can be repurposed for various drugs.

When combined, this technology optimizes therapies, offering promise for combating addiction and mental health illnesses in addition to effective pain management.

How is Subcutaneous Ketamine a Powerful
Option for Pain Management?

Potency that rivals powerful opioids with an improved safety profile and reduced risk of physical addiction

Pharmacology that may treat acute pain and prevent development of chronic pain

Literature data establishes efficacy across multiple pain sub-types

Improved safety profile compared to opioids

Evolving Medicine Enhancing Lives

Bexson’s subcutaneous ketamine delivery system to address pain management is our priority focus. However, our proprietary formulation and delivery technology can help repurpose other valuable therapies to treat multiple large market indications.

Bexson Biomedical is developing a unique ketamine delivery system for pain disorders and mental health conditions. Our flagship project will deliver a proprietary subcutaneous formulation of ketamine via a minimally invasive, wearable, subcutaneous infusion pump to enable highly accurate delivery and dosing control.

© Bexson Biomedical  2021.  All Rights Reserved.   PrivacyTerms